- P.N.L. Lens (1)
- T.M. Marques (1)
- I. Rangel (2)
- J. Sundin (2)
- A.H.M. Veeken (1)
- W.M. Vos de (2)
- Willem Vos de (1)
- R. Wall (1)
Correlating the Gut Microbiome to Health and Disease
Marques, T.M. ; Holster, S. ; Wall, R. ; König, J. ; Brummer, R.J. ; Vos, Willem de - \ 2016
In: The Gut-Brain Axis Dietary, Probiotic, and Prebiotic Interventions on the Microbiota Elsevier Inc. Academic Press - ISBN 9780128025444 - p. 261 - 291.
Gut microbiota - Immune system-related diseases - Intestinal diseases - Metabolic diseases - Nervous system-related diseases - Therapies for gut microbiota modulation
The gut microbiota is a complex ecosystem consisting of a diverse population of prokaryotes that has a symbiotic relationship with its host; thus it plays a vital role for the host's health. Our understanding of the effect of the gut microbiome in health and disease has grown substantially over the past 2 decades, mostly because of recent advances in sequencing and other high-throughput technologies. Given its high metabolic potential, close proximity to the intestinal mucosa, and interaction with the immune system, it is not surprising that the gut microbiome is an important partaker in human health. Evidence to the importance of the gut microbiome in human health and disease is the growing number of conditions now linked to changes in the resident gut microbiota, including recurrent Clostridium difficile infections, inflammatory bowel disease, irritable bowel syndrome, colorectal cancer, allergies, neurological diseases, and metabolic diseases. Research into this field of the association of the gut microbiome with health and disease continues to expand at a rapid pace as we come to accept the gut microbiome as our "second genome." Targeting the gut microbiome to restore/modulate its composition with the use of antibiotics, probiotics, prebiotics, and even fecal microbiota transplantation is considered a promising future strategy for the development of new solutions in the treatment of various diseases associated with an imbalance in microbiota composition and functioning.
PP130-sun differences in intestinal mucosal and faecal microbiota in patients with irritable bowel syndrome
Rangel, I. ; Fuentes Enriquez de Salamanca, S. ; König, J. ; Sundin, J. ; Vos, W.M. de; Brummer, R.J. - \ 2013
Clinical Nutrition 32 (2013)S1. - ISSN 0261-5614 - p. S71 - S71.
PP114-sun altered intestinal microbiota in PI-IBS patients
Sundin, J. ; Fuentes Enriquez de Salamanca, S. ; Rangel, I. ; Vos, W.M. de; König, J. ; Brummer, R.J. - \ 2013
Clinical Nutrition 2 (2013)S1. - ISSN 0261-5614 - p. S65 - S65.
Dynamic modelling and process control of ZnS precipitation
König, J. ; Keesman, K.J. ; Veeken, A.H.M. ; Lens, P.N.L. - \ 2006
Separation Science and Technology 41 (2006)6. - ISSN 0149-6395 - p. 1025 - 1042.
reducing bacterial biofilms - sulfate reduction - heavy-metals - reactor - accumulation
This paper presents the dynamic modelling and design of a control strategy for the ZnS precipitation process. During lab¿scale experiments, the sulfide concentration in a precipitator was controlled at a prespecified pS value by manipulating the flow from a buffer vessel. Batch tests showed that the optimal condition for zinc sulfide precipitation is at a sulfide concentration of 10¿15 mole/l (pS 15). Experiments with the precipitator showed that the sulfide concentration highly deviates from a given setpoint when proportional (P) control is used, but this deviation can be decreased using a Proportional Integral (PI) controller. Moreover, the PI controller was able to handle sudden disturbances in the process conditions (pH, influent flow rate, or zinc and sulfide concentration). Additional precipitation experiments were conducted using effluent from a sulfate reducing gas¿lift reactor to determine if the compounds present in the effluent influence the control process. With the gas¿lift reactor effluent and a PI controller, the desired sulfide concentration was reached almost instantaneously (within 15 minutes) within acceptable margins (2¿5%)